InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Completes QM CoRE(TM) Integration
January 6, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”) novel active-learning Computational Research Engine (CoRE(TM)). According to the update, CoRE was integrated with Helomics’ proprietary TumorSpace(TM) knowledgebase of 150,000 […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Engages Investor Relations Firm
January 5, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that it has hired an investor relations firm. POAI has chosen Landon Capital to provide investor relations services; the agreement was effective Dec. 30, 2020. The announcement noted that anticipated services would include introductions to […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Cancels Upcoming Special Meeting of Stockholders
December 30, 2020
Predictive Oncology’s (NASDAQ: POAI) Board of Directors has announced that it will cancel the Special Meeting of Stockholders that was scheduled for today. Originally scheduled for Dec. 1, 2020, the meeting was adjourned on that date and rescheduled for Dec. 30 because a quorum had not been reached. As of the rescheduled date, the required […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Integrates Data, AI to Pave Path for Better Health Outcomes
December 23, 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, is positioned to play a critical role in the precision oncology industry. The company integrates AI technology with oncologists’ clinical decision-making processes, paving the way for improved health outcomes. A recent article […]
Predictive Oncology (NASDAQ: POAI) Adjourns Special Virtual Meeting; CEO Requesting Shareholder Vote for Critical Tax-Related Proposal
December 21, 2020
POAI sent letter to shareholders requesting attendance at virtual Special Meeting on December 30, 2020 Meeting will address reincorporation of POAI in Nevada Reincorporation expected to save POAI approximately $158,000 annually in state taxes Shareholders can vote online or by telephone, detailed instructions outlined in proxy materials Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shines Spotlight on Innovative Media in Exclusive Interview
December 18, 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, was recently featured in an exclusive audio interview with NetworkNewsWire. During the interview, POAI CEO Carl Schwartz noted recent milestones, outlined strategic goals and provided key updates on the company’s four impressive […]
Predictive Oncology (NASDAQ: POAI) Leverages Precision Medicine Expertise to Support Oncologists, Improve Patient Outcomes
December 17, 2020
Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics. New approach allows doctors, researchers to predict more accurately which treatments may work better. Helomics’ database, largest of its kind, is comprised of ovarian, head and neck, colon and pancreas tumors. Science has discovered that thumbprints and DNA aren’t the only […]
Using AI-Powered Models and Drug-Response Data, Predictive Oncology (NASDAQ: POAI) Holds Strong Position in Burgeoning Precision Oncology Industry
December 15, 2020
Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report POAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for […]
Predictive Oncology (NASDAQ: POAI) Releases Third-Quarter 2020 Business Update, Financial Report
December 10, 2020
Financial numbers show revenues stay level, gross margins up and operations expenses down. Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery. POAI subsidiaries all showing progress, growth in key areas. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting
December 9, 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s […]
InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations
December 8, 2020
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Special Stockholder Meeting, Urges Stockholder Voting
December 2, 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its virtual Special Meeting of Stockholders, which was scheduled for Dec. 1, 2020, was held but no business was conducted because a full quorum was not in attendance. The meeting has been rescheduled for […]
Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems
November 25, 2020
Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates
November 17, 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020. The report included a note that revenues of $0.5 million were level with the third quarter of last year, primarily […]
Predictive Oncology (NASDAQ: POAI) CEO Discusses Subsidiaries’ Proprietary Tech, Innovative Media
November 16, 2020
CEO expects results that will “build the stock and raise the stock price” POAI focused on positioning TumorGenesis kits to manufacturers Helomics has largest database of its kind in the world, brings cutting-edge technology to cancer research During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care
November 12, 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company, focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid in clinical decision-making and […]
Predictive Oncology (NASDAQ: POAI) CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiaries
November 11, 2020
Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospects Schwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates decline TumorGenesis received overwhelmingly positive feedback on its initial product launches, with plans to extend its technological prowess to address other oncological […]
Predictive Oncology (NASDAQ: POAI) Subsidiary’s HSC Technology Optimization Solution Offers Unparalleled Results, Benefits
November 6, 2020
POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition Results garnered from company’s HSC optimization are unparalleled in field Soluble Biotech lands first major contract, signifying major company milestone Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview
October 27, 2020
Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: […]